|Trade names||Vfend, others|
|IV, by mouth (tablet, suspension)|
|Metabolism||Liver: CYP2C19 (significant involvement), also CYP2C9, CYP3A4|
|Metabolites||Voriconazole N-oxide (major; minimal antifungal activity)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||349.317 g·mol−1|
|3D model (JSmol)|
Voriconazole, sold under the brand name Vfend among others, is an antifungal medication used to treat a number of fungal infections. This includes aspergillosis, candidiasis, coccidioidomycosis, histoplasmosis, penicilliosis, and infections by Scedosporium or Fusarium. It can be taken by mouth or used by injection into a vein.
Common side effects include vision problems, nausea, abdominal pain, rash, headache, and seeing or hearing things that are not present. Use during pregnancy may result in harm to the baby. It is in the triazole family of medications. It works by affecting fungal metabolism and fungal cell membranes.
Voriconazole was patented in 1990 and approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. The wholesale cost in the United States, as of 2019, is about US$9 per day.
Voriconazole is used to treat invasive aspergillosis and candidiasis and fungal infections caused by Scedosporium and Fusarium species, which may occur in immunocompromised patients, including people undergoing allogeneic bone marrow transplant (BMT), who have hematologic cancers or who undergo organ transplants.
It is also the recommended treatment for the CNS fungal infections transmitted by epidural injection of contaminated steroids.
It can be taken by mouth or given in a doctor's office or clinic by intravenous infusion.
It is toxic to the fetus; pregnant women should not take it and women taking it should not become pregnant.
People who have hereditary intolerance for galactose, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this drug. It should be used with caution in people with arrhythmias or long QT.
No dose adjustment is necessary for renal impairment or advanced age, but children seem to clear voriconazole faster than adults and drug levels may need monitoring.
The labels carry several warnings of the risk of injection site reactions, hypersensitivity reactions; kidney, liver, and pancreas damage; trouble with vision; and adverse effects in skin including damage due to phototoxicity, squamous cell skin cancer, and Stevens–Johnson syndrome; in long-term use there is a warning of the risk of bone fluorosis and periostitis.
Additionally, very common adverse effects, occurring in more than 10% of people, include peripheral edema, headaches, trouble breathing, diarrhea, vomiting, abdominal pain, nausea, rashes, and fever.
Common adverse effects, occurring in between 1 and 10% of people, include sinus infections, low numbers of white and red blood cells (agranulocytosis, pancytopenia, thrombocytopenia, leukopenia, and anemia), low blood sugar, reduced amount of potassium and sodium, depression, hallucinations, anxiety, insomnia, agitation, confusion, convulsions, fainting, tremor, weakness, tingling, sleepiness, dizziness, bleeding retina, irregular heart beats, slow or fast heart beats, low blood pressure, inflamed veins, acute respiratory distress syndrome, pulmonary edema, inflamed lips, swollen face, stomach upset, constipation, gingivitis, jaundice, hair loss, flaky skin, itchiness, red skin, back pain, chest pain, and chills.
Being metabolized by hepatic cytochrome P450, voriconazole interacts with many drugs. Voriconazole should not be used in conjunction with many drugs (including sirolimus, rifampicin, rifabutin, carbamazepine, quinidine and ergot alkaloids) and dose adjustments and/or monitoring should be done when coadministered with others (including fluconazole, warfarin, ciclosporin, tacrolimus, omeprazole, and phenytoin). Voriconazole may be safely administered with cimetidine, ranitidine, indinavir, macrolide antibiotics, mycophenolate, digoxin and prednisolone.
Voriconazole is well absorbed orally with a bioavailability of 96%, allowing patients to be switched between intravenous and oral administration.
Pfizer brought the drug to market as Vfend. A generic version of the tablet form of voriconazole was introduced in the US in 2011 after Pfizer and Mylan settled litigation under the Hatch-Waxman Act; a generic version of the injectable form was introduced in 2012. In Europe patent protection expired in 2011 and pediatric administrative exclusivity expired in Europe in 2016.
Society and culture
As of July 2017 the drug was marketed under the following names worldwide: Cantex, Pinup, Vedilozin, Vfend, Vodask, Volric, Voramol, Voriconazol, Voriconazole, Voriconazolum, Voricostad, Vorikonazol, Voritek, Voriz, Vornal, and Vosicaz.
- "US voriconazole label" (PDF). FDA. June 2017. Retrieved 30 July 2017. For label updates see FDA index page for NDA 021630
- "Voriconazole". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.
- Kendig, Edwin L.; Wilmott, Robert W.; Chernick, Victor (2012). Kendig and Chernick's Disorders of the Respiratory Tract in Children. Elsevier Health Sciences. p. 539. ISBN 978-1437719840.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 503. ISBN 9783527607495.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "NADAC as of 2019-08-21". Centers for Medicare and Medicaid Services. Retrieved 2019-09-23.
- "Vfend tablet and powder". UK Electronic Medicines Compendium. January 2017. Retrieved 30 July 2017.
- Patterson, TF; Thompson GR, 3rd; Denning, DW; Fishman, JA; Hadley, S; Herbrecht, R; Kontoyiannis, DP; Marr, KA; Morrison, VA; Nguyen, MH; Segal, BH; Steinbach, WJ; Stevens, DA; Walsh, TJ; Wingard, JR; Young, JA; Bennett, JE (15 August 2016). "Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases. 63 (4): e1–e60. doi:10.1093/cid/ciw326. PMC 4967602. PMID 27365388.
- Omrani, AS; Almaghrabi, RS (13 June 2017). "Complications of hematopoietic stem transplantation: Fungal infections". Hematology/Oncology and Stem Cell Therapy. 10 (4): 239–244. doi:10.1016/j.hemonc.2017.05.013. PMID 28636889.
- Herbrecht, R; Denning, DW; Patterson, TF; Bennett, JE; Greene, RE; Oestmann, JW; Kern, WV; Marr, KA; Ribaud, P; Lortholary, O; Sylvester, R; Rubin, RH; Wingard, JR; Stark, P; Durand, C; Caillot, D; Thiel, E; Chandrasekar, PH; Hodges, MR; Schlamm, HT; Troke, PF; de Pauw, B (8 August 2002). "Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis" (PDF). The New England Journal of Medicine. 347 (6): 408–15. doi:10.1056/NEJMoa020191. hdl:2066/185528. PMID 12167683.
- "Interim Treatment Guidance for Central Nervous System and Parameningeal Infections Associated with Injection of Contaminated Steroid Products". Centers for Disease Control and Prevention. Retrieved 6 November 2016.
- Smith, J; Safdar, N; Knasinski, V; Simmons, W; Bhavnani, SM; Ambrose, PG; Andes, D (April 2006). "Voriconazole Therapeutic Drug Monitoring". Antimicrobial Agents and Chemotherapy. 50 (4): 1570–2. doi:10.1128/AAC.50.4.1570-1572.2006. PMC 1426935. PMID 16569888.
- "Vfend loses its paediatric protection" (PDF). IMS Health Generics Bulletin. 22 July 2016.
- "Voriconazole international brand names". Drugs.com. Retrieved 30 July 2017.
- Dean L (December 2019). "Voriconazole Therapy and CYP2C19 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 31886997.
- "Voriconazole". Drug Information Portal. U.S. National Library of Medicine.